Literature DB >> 22821878

DOTAM-type ligands possessing arginine pendant groups for use in PARACEST MRI.

Mojmír Suchý1, Alex X Li, Mark Milne, Robert Bartha, Robert H E Hudson.   

Abstract

A synthetic methodology was developed for the preparation of metal-chelating ligands that possess arginine pendant groups relying on the alkylation of 1,4,7,10-tetraazacyclododecane (cyclen) with arginine-containing electrophiles. Conditions for the selective trialkylation or peralkylation of cyclen are described, the outcome being dependent on the nature of the arginine-derived electrophile and the solvent used for the reaction. Lanthanide metal complexes of the ligands prepared by the described route were evaluated for their suitability as PARACEST contrast agents for use in magnetic resonance imaging. The Dy(3+) and Tm(3+) complexes display CEST effects that are associated with the amide protons proximate to the metal center. These signals exhibit pH dependence in the range of 6.0-8.0 and thus may have the potential for pH measurement in physiological range.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22821878     DOI: 10.1002/cmmi.1461

Source DB:  PubMed          Journal:  Contrast Media Mol Imaging        ISSN: 1555-4309            Impact factor:   3.161


  3 in total

1.  Evaluating pH in the Extracellular Tumor Microenvironment Using CEST MRI and Other Imaging Methods.

Authors:  Liu Qi Chen; Mark D Pagel
Journal:  Adv Radiol       Date:  2015

2.  Correlation of Solid State and Solution Coordination Numbers with Infrared Spectroscopy in Five-, Six-, and Eight-Coordinate Transition Metal Complexes of DOTAM.

Authors:  Maika K C T Nagata; Paul S Brauchle; Sen Wang; Sarah K Briggs; Young Soo Hong; Daniel W Laorenza; Andrea G Lee; T David Westmoreland
Journal:  Polyhedron       Date:  2016-08-16       Impact factor: 3.052

Review 3.  Enhancing magnetic resonance imaging with contrast agents for ultra-high field strengths.

Authors:  Akhila N W Kuda-Wedagedara; Matthew J Allen
Journal:  Analyst       Date:  2014-09-21       Impact factor: 4.616

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.